Comparative Pharmacology
Head-to-head clinical analysis: TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE versus XIMINO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE versus XIMINO.
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE vs XIMINO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate synthesis and thereby inhibiting thymidine synthesis. Polymyxin B disrupts bacterial cell membrane integrity by binding to lipopolysaccharides in Gram-negative bacteria.
XIMINO is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
One drop in each affected eye every 2 to 4 hours for 7 to 10 days.
400 mg orally twice daily with food for 7 days.
None Documented
None Documented
Trimethoprim: 8-10 hours (normal renal function); Polymyxin B: 6 hours (prolonged in renal impairment).
Terminal elimination half-life: 8 hours (range 6-10 hours) in healthy adults; prolonged to 15-20 hours in severe renal impairment (CrCl <30 mL/min).
Trimethoprim: renal (80-90% unchanged, 10-20% metabolites); Polymyxin B: renal (60% unchanged, 40% nonrenal).
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites and unchanged drug; 10% metabolized via hepatic CYP3A4.
Category D/X
Category C
Antibiotic
Antibiotic